期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ijms23094511
关键词
glioblastoma; glioma stem cell; SOX9; therapy; transcriptome; STAT3; PML; pharmacological inhibition
资金
- AECC foundation
- Carlos III Institute (ISCIII)
- ISCIII
- Stop Fuga de Cerebros postdoctoral fellowship
- Miguel Servet contract from the ISCIII [CP19/00085]
- Biodonostia Health Research Institute
- FEDER Funds [CP19/00085, CP16/00039, DTS16/00184, PI16/01580, DTS18/00181, PI18/01612]
- Industry and Health Departments of the Basque Country
SOX9 is a critical transcription factor associated with poor survival in glioma patients. Knockdown of SOX9 impairs glioma stem cell proliferation, suggesting its potential as a therapeutic target. This study reveals a regulatory loop involving SOX9, STAT3, and PML that is essential for glioma stem cell activity and self-renewal. Inhibition of STAT3 or PML reduces the expression of SOX9, STAT3, and PML proteins, leading to decreased tumorigenicity in glioma stem cells.
Glioma stem cells (GSCs) are critical targets for glioma therapy. SOX9 is a transcription factor with critical roles during neurodevelopment, particularly within neural stem cells. Previous studies showed that high levels of SOX9 are associated with poor glioma patient survival. SOX9 knockdown impairs GSCs proliferation, confirming its potential as a target for glioma therapy. In this study, we characterized the function of SOX9 directly in patient-derived glioma stem cells. Notably, transcriptome analysis of GSCs with SOX9 knockdown revealed STAT3 and PML as downstream targets. Functional studies demonstrated that SOX9, STAT3, and PML form a regulatory loop that is key for GSC activity and self-renewal. Analysis of glioma clinical biopsies confirmed a positive correlation between SOX9/STAT3/PML and poor patient survival among the cases with the highest SOX9 expression levels. Importantly, direct STAT3 or PML inhibitors reduced the expression of SOX9, STAT3, and PML proteins, which significantly reduced GSCs tumorigenicity. In summary, our study reveals a novel role for SOX9 upstream of STAT3, as a GSC pathway regulator, and presents pharmacological inhibitors of the signaling cascade.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据